Healthy volunteers help compare two forms of experimental drug amlitelimab
NCT ID NCT05796479
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study tested two different versions of the experimental drug amlitelimab in 32 healthy adults. The goal was to see how the body absorbs and processes each version and to check for any safety issues. Participants received a single injection and were monitored for about 17 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- amlitelimab
- What could go wrong
- This is an early-phase study in healthy volunteers, not patients, so it cannot show whether the drug works for any disease. The main goal is just to compare two versions of the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Pharmacology of Miami-Site Number: 8400001
Hialeah, Florida, 33014, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults